Multiplate Platelet Assay Interpretation    body {font-family: 'Open Sans', sans-serif;}

### Multiplate Platelet Assay Interpretation

**Measuring Parameter: U:** (aggregated unit)  
  
**ASPI test  
U:** (aggregated unit)

table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| 71-115 U | Normal Range |
| --- | --- |
| < 40 U | Platelet inhibition by COX-1 (aspirin) |
| < 30 U | Strong platelet inhibition by COX-1 (aspirin) |

**ADP test**

table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| 57-113 U | Normal Range |
| --- | --- |
| \> 46 U | High thrombotic risks in percutaneous  
coronary intervention (PCI), high  
platelet reactivity |
| < 31 U | High bleeding risks in CABG |
| < 19 U | High bleeding risk in PCI |

  

Cut-off values ADPtest and ASPItest  
Roche Diagnostics International Ltd  
http://www.haemoview.com.au/uploads/2/5/4/9/25498232/roche\_multiplate\_smartcard-a6\_verum\_v2\_screen\_es.pdf  
  
ADPtest Package Insert (06673686001V2), 2012, Roche Diagnostics GmbH.  
  
ASTItest Package Insert  
  
Sibbing, D., et al., Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. _J Am Coll Cardiol, 2009. 53(10):_ p. 849-856  
  
Al-Azzam, S.I., et al., The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin. _Acta Cardiol, 2012. 67(4):_ p. 445-448.